Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration.
Inflammation and iron accumulation in the substantia nigra (SN) are implicated in the pathogenesis of Parkinson's disease (PD). However, the relationship between neuroinflammation and iron mismanagement remain largely unknown. In the present study, an animal model induced by lipopolysaccharide (LPS) was used to evaluate iron concentration in the ventral midbrain with or without neuroinflammation. Furthermore, the iron chelator desferrioxamine (DFO) was used to explore its neuroprotective property against LPS-induced nigrostriatal degeneration. Adult C57BL/6 mice were treated with DFO (2.5 µg) commenced 3 days prior to or following microinjection of LPS into the striatum. Animal behavioral tests, as well as pathological and biochemical assays were performed to evaluate the nigrostriatal dopamine neuron degeneration and neuroprotective effects of DFO. Here, we report that the iron concentration in the ventral midbrain significantly increased following intrastriatal injection of LPS, and administration of DFO improved behavior deficits, attenuated dopamine (DA) neuron loss and striatal DA reduction, and alleviated microglial activation in the SN. These results suggest that DFO may possess neuroprotective effect against LPS-induced nigrostriatal dopamine neuron degeneration.